ABC TRANSPORTERS · Implementation of a pharmacogenomic approach to predict ABC transporter substrates and compounds selectively targeting multidrug resistant cancer
6РП — Действия „Мария Кюри“
- Период
- 2007-01-01 → 2008-12-31
- Финансиране от ЕС
- 111 256 €
- Участници
- 1
- Схема
- EIF
Линиите свързват координатора с партньорите. За проекти отпреди 2014 г. CORDIS не винаги дава точни координати. Тези точки са на ниво град или държава.
Накратко на български
Протеините от фамилията ABC транспортират лекарства извън раковите клетки, което ги прави устойчиви на химиотерапия. Разбирането на този механизъм помага при избора на подходящи препарати за лечение на пациенти с многолекарствена резистентност.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Final Activity Report Summary - ABC TRANSPORTERS (Implementation of a pharmacogenomic approach to predict ABC transporter substrates and compounds selectively targeting multidrug resistant cancer)
The major challenge of the post genomic era is to analyse vast amounts of data. In this context, the application of pharmacogenetics has the potential to improve the management of patients, particularly by providing the molecular basis for choosing among the increasing number of chemotherapeutic agents available for the treatment. Despite considerable advances in drug discovery, resistance to chemotherapy confounds the effective treatment of cancer patients. Cancer cells can become resistant to a single drug or they may acquire broad cross-resistance to mechanistically and structurally unrelated drugs, referred to as multidrug resistance (MDR). ATP-binding cassette (ABC) proteins comprise the largest protein family, many members of which are of immediate medical importance and relevant to human health. The major aim of this project was to apply a pharmacogenomic approach to discover ABC transporter substrates and MDR1-inverse compounds that selectively killed multidrug resistant cancer cells. The results could be summarised as follows: 1. we delineated defining features of candidate ABC transporter substrates, 2. we proposed a mechanism of action for the toxicity of newly identified MDR1-inverse compounds and 3. we developed models and transport assays for the study of drug-transporter interactions.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Although considerable progress has been made in treating cancer over the past decade, there are still over 8 million deaths annually from cancer worldwide. Despite considerable advances in drug discovery, resistance to chemotherapy confounds the effective treatment of cancer patients.Cancer cells can become resistant to a single drug or they may acquire broad cross-resistance to mechanistically and structurally unrelated drugs. ATP-binding cassette (ABC) proteins comprise the largest protein family, many m embers of which are of immediate medical importance. In particular, ABCB1 (MDR1-Pgp) actively extrudes many types of drugs from cancer cells, thereby conferring resistance to those agents.Thus, innate or acquired expression of P-gp is a major problem in cancer chemotherapy. ABCC2/MRP2 plays a pivotal role in the export of organic anions, bile acids and xenobiotics into the bile and also contributes to protection against orally ingested drugs. The substrate specificity of MRP2 has been widely investigated in the research community. The major challenge of the postgenomic era is to analyze vast amounts of data.In this context, the application of pharmacogenetics has the potential to improve the management of patients, particularly by providing the molecular basis for choosing among the increasing number of chemotherapeutic agents available for the treatment. The basic hypothesis of this proposal is that a pharmacogenomic approach can be exploited to characterize ABCC2/MRP2 substrates and to discover MDR1-inver se compounds that selectively kill multidrug resistant cancer cells.The proposed research utilizes a complex array of methodological tools involving chemoinformatics, a custom-made microarray, and biochemical assays for measuring and characterizing transport. These aims will help in determining the mechanism of action of MDR1-inverse compounds, setting the stage for a fresh therapeutic approach that may eventually translate into improved patient care.
Оригинален текст от CORDIS (на английски).
Участници
- INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES · BUDAPESTКоординаторНиво градУнгария
Връзки
Данни: CORDIS, © Европейски съюз